IDiyas

For the Inventor, By the Inventor

Rockville, MD, United States of America

Mira Jung

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 26(Granted Patents)


Company Filing History:

goldMedal9 out of 9 
 
Shuttle Pharmaceuticals, Inc.
 patents
silverMedal5 out of 484 
 
Georgetown University
 patents
bronzeMedal1 out of 2,340 
 
University of Illinois
 patents
where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents
1. 12357650 - Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation (2025-07-15),
2. 12077515 - Selective histone deacetylase inhibitors for the treatment of human disease (2024-09-03),
3. 11654157 - Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation (2023-05-23),
4. 11584733 - Selective histone deacetylase inhibitors for the treatment of human disease (2023-02-21),
5. 11407723 - Selective histone deacetylase inhibitors for the treatment of human disease (2022-08-09),
6. 11034667 - Selective histone deacetylase inhibitors for the treatment of human disease (2021-06-15),
7. 10745352 - Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof (2020-08-18),
8. 10730834 - Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof (2020-08-04),
9. 9809539 - Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof (2017-11-07),
10. 8748463 - Histone deacetylase inhibitors and methods of use thereof (2014-06-10),
11. 8653278 - Isoform selective HDAC inhibitors (2014-02-18),
12. 8293513 - Histone deacetylase inhibitors (2012-10-23),
13. 8222451 - Histone deacetylase inhibitors and methods of use thereof (2012-07-17),
14. 7842835 - Histone deacetylase inhibitors and methods of use thereof (2010-11-30),

Title: Mira Jung: Innovator in Cancer Therapy

Introduction

Mira Jung is a prominent inventor based in Rockville, MD (US), known for her significant contributions to cancer therapies. With a total of 14 patents, she has made remarkable strides in the field of medical innovation.

Latest Patents

Among her latest patents are groundbreaking methods and compositions for cancer therapies that include the delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation. These methods and formulations are designed to treat cancer and neoplastic diseases alongside radiation therapy, utilizing a radiosensitizing agent metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor to enhance the agent's half-life. Additionally, she has developed selective histone deacetylase inhibitors for the treatment of various human diseases, including cancer, immunological diseases, inflammatory diseases, and neurological diseases.

Career Highlights

Mira has worked with notable organizations such as Shuttle Pharmaceuticals, Inc. and Georgetown University. Her work in these institutions has been pivotal in advancing cancer treatment methodologies.

Collaborations

Mira has collaborated with esteemed colleagues, including Anatoly Dritschilo and Scott Grindrod, further enhancing her research and development efforts in the medical field.

Conclusion

Mira Jung's innovative work in cancer therapies showcases her dedication to improving patient outcomes through advanced medical research. Her contributions continue to influence the landscape of cancer treatment and inspire future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…